| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin Poultice 100mg Receives Approval for Manufacture TOKYO, JAPAN -- January 24, 2006 -- The percutaneous absorption-type analgesic and anti-inflammatory preparation Loxonin poultice 100mg (generic name: loxoprofen sodium) which was jointly developed by Lead Chemical Co., Ltd. and a Daiichi Sankyo Company, Limited group subsidiary Sankyo Co., Ltd. has been approved for manufacture today. Among poultice preparations containing nonsteroidal anti-inflammatory drugs (NSAIDs), it is the first poultice for usage once per day to be granted approval for manufacture. Loxonin poultice is a hydrophilic preparation containing the same constituents as Loxonin pills and Loxonin powder, which is one of the leading brands among orally administered analgesic and anti-inflammatory drugs in Japan. As it is applied once per day, we expect there will be an improvement in user compliance. This preparation is scheduled to be manufactured by Lead Chemical and sold by Sankyo.
SOURCE: Daiichi Sankyo Company, Limited
|